Head and neck carcinoma
MONDO:0002038A carcinoma that arises from the head and neck region. Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
Also known as: carcinoma of craniocervical region, carcinoma of head and neck, carcinoma of neck, carcinoma of the head and neck, craniocervical region carcinoma, head and neck carcinoma, neck carcinoma, carcinoma of the neck
3925 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 826 trials in this tab.
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Blood test could guide chemo for throat cancer patients
Disease control OngoingThis study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Cancer drug targets genetic weakness in advanced tumors
Disease control OngoingThis phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
A gentler path after surgery for HPV throat cancer?
Disease control OngoingThis phase 2 trial is testing whether people with HPV-related throat cancer can safely receive lower doses of radiation and chemotherapy after surgery, compared with the standard full-intensity approach. The goal is to see if this lighter treatment helps preserve swallowing funct…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can an immunotherapy boost standard treatment for a Head-and-Neck cancer?
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can improve outcomes for people with locally advanced nasopharyngeal carcinoma, a type of head-and-neck cancer. Participants will receive either toripalimab or a…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
Disease control OngoingThis trial is testing whether giving an extra round of chemotherapy before the usual chemoradiotherapy can improve outcomes for people with a certain type of nasopharyngeal cancer. Participants will either receive standard chemoradiotherapy alone or induction chemotherapy (gemcit…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can less radiation be safer for throat cancer?
Disease control OngoingThis trial tests whether giving radiation to a smaller area of the neck can prevent throat cancer from returning while reducing side effects. People with p16-positive oropharynx cancer (a type linked to HPV) who are getting radiation therapy may be eligible. The goal is to see if…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control OngoingThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for advanced head and neck cancer: drug combo trial launches
Disease control ENROLLING_BY_INVITATIONThis study tests a combination of the targeted drug amivantamab plus two chemotherapy drugs (carboplatin and paclitaxel) in 50 people with head and neck cancer that has come back or spread. The goal is to see if this treatment shrinks tumors or controls the disease. Participants …
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
Disease control OngoingThis phase II trial is investigating whether giving immunotherapy before surgery can boost the immune system's attack on head and neck squamous cell carcinoma. Participants receive atezolizumab alone or combined with other immune-modulating agents, then undergo surgery. The study…
Phase: PHASE2 • Sponsor: Alain Algazi • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental cancer combo targets Hard-to-Treat tumours
Disease control OngoingThis early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control ENROLLING_BY_INVITATIONThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New cancer drug SG2918 enters first human tests
Disease control OngoingThis early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer vaccine plus immunotherapy shows promise in Hard-to-Treat cancers
Disease control OngoingThis study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Engineered immune cells take on advanced cancers in early trial
Disease control OngoingThis early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New trial tests shorter radiation for head and neck cancer that has returned
Disease control TerminatedThis phase II trial compares two types of radiation for people whose head and neck cancer has come back and cannot be removed with surgery. One method delivers high-dose radiation in fewer sessions, while the other uses standard daily doses over several weeks. The study aims to s…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
Disease control OngoingThis phase II trial is exploring whether combining stereotactic body radiation therapy (SBRT) with the immunotherapy drug tislelizumab, given before surgery, can help people with locally advanced head and neck squamous cell carcinoma. The study will enroll about 24 adults aged 18…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug combo targets Hard-to-Treat tumors
Disease control TerminatedThis early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called 9-ING-41, when combined with the chemotherapy drug carboplatin, can help people with advanced or metastatic salivary gland cancer. The study aims to see if the combination can shrink tumors or slow their growth. Pa…
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control OngoingThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cancer drug olaparib gets a makeover: which pill works best?
Disease control OngoingThis phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug ONO-7428 enters first human tests for advanced cancers
Disease control OngoingThis early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Milder treatment after robotic surgery may cut side effects for HPV throat cancer patients
Disease control OngoingThis study tests a less intense version of standard chemo-radiation for people with HPV-positive throat cancer who have had robotic surgery to remove visible tumors. The goal is to see if the milder treatment works just as well as the standard dose but causes fewer side effects. …
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase: PHASE1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo tested against hard-to-treat cancers
Disease control OngoingThis early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control OngoingThis trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
Disease control OngoingThis study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control TerminatedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control OngoingThis early-phase trial tests a new drug called BI 765179, an antibody that helps the immune system fight cancer. It is given alone or with other drugs (ezabenlimab or pembrolizumab) to adults with advanced solid tumors or head and neck cancer. The study aims to find the best dose…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental drug combo aims to fight returning head and neck tumors
Disease control OngoingThis early-phase trial tests a drug called birinapant together with a second course of targeted radiation for people whose head and neck cancer has come back in the same area. The drug works by blocking a protein that helps cancer cells survive. The main goals are to find the saf…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immunotherapy combo may keep head and neck cancer at bay
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab before and after surgery can help people with advanced head and neck cancer stay cancer-free longer. About 714 participants receive either pembrolizumab plus standard radiation (with or without chemo) or…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy drug may save eyes from aggressive skin cancer
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this condition will receive the drug. The goal is to see if the cancer responds and if the eye can be saved from surgery.
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a baking soda rinse tame radiation mouth sores?
Disease control OngoingThis study tests whether gargling with a 2.5% sodium bicarbonate (baking soda) solution during radiation therapy can reduce the severity of painful mouth sores in people with nasopharyngeal carcinoma. Participants will rinse with the solution several times a day throughout their …
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
Disease control OngoingThis phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that cannot be removed by surgery or has spread. The goal is to find the best dose and see if the combination can shrink tumors. Twenty-three participants are enr…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could less radiation be better? new trial spares healthy neck tissue
Disease control OngoingThis phase 2 trial tests whether it is safe to skip radiation on one or both sides of the neck that show no signs of cancer after surgery. The goal is to reduce side effects like dry mouth and trouble swallowing without increasing the chance of cancer returning. The study include…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase: PHASE2, PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a short course of immunotherapy and radiation shrink head and neck tumors before surgery?
Disease control OngoingThis trial investigates whether giving the immunotherapy drug nivolumab along with a short course of radiation before surgery can safely shrink tumors and reduce lymph node involvement in people with head and neck squamous cell carcinoma. Participants receive either 3 or 5 days o…
Phase: PHASE1, PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase: PHASE1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Targeted drug takes aim at NF1-Mutated cancers
Disease control OngoingThis phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immunotherapy boost before surgery shows promise against head and neck cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for thr…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Pea power: Plant-Based drink may cut feeding tube need in cancer patients
Disease control OngoingThis study tests whether a pea protein nutritional drink can reduce the need for feeding tubes in people with head and neck cancer undergoing chemoradiation. About 57 adults with locally advanced cancer will drink the supplement as a meal replacement. The goal is to see if it hel…
Phase: NA • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental antibody combo aims to boost immune attack on head and neck tumors
Disease control OngoingThis phase 1 trial tests whether adding an experimental antibody called VX15/2503 to standard immunotherapy drugs (ipilimumab or nivolumab) can help shrink head and neck cancers before surgery. The study enrolls people with early-stage (I-IVA) squamous cell carcinoma of the head …
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail targets advanced cancers in early trial
Disease control OngoingThis Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to boost immune attack on HPV throat cancer before surgery
Disease control OngoingThis phase 2 trial tests whether giving targeted radiation along with two immunotherapy drugs (evorpacept and pembrolizumab) before standard surgery can improve outcomes for people with HPV-related throat cancer. The study enrolls 29 patients with early-stage, resectable disease.…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New proton beam therapy aims to zap head and neck cancer with fewer side effects
Disease control OngoingThis study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Sharper radiation boost aims to tackle head and neck cancers that return
Disease control OngoingThis phase 1 study tests whether adding a highly targeted, high-dose radiation boost (stereotactic body radiotherapy, or SBRT) to standard radiation and chemotherapy can safely treat head and neck cancer that has come back or spread. The trial includes two groups: patients whose …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase: PHASE1, PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase: PHASE1 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
Disease control OngoingThis trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal cancer. Participants receive three cycles of toripalimab plus gemcitabine and cisplatin, then undergo standard…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase: PHASE1, PHASE2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Targeted drug palbociclib tested against cancers with specific genetic flaw
Disease control OngoingThis phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered virus joins forces with immunotherapy to fight resistant cancers
Disease control OngoingThis phase 2 trial tests whether a modified virus (VV1) combined with the immunotherapy drug cemiplimab can shrink tumors in people with colorectal cancer, head and neck squamous cell carcinoma, or melanoma that has stopped responding to checkpoint inhibitor treatment. The virus …
Phase: PHASE2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Pushing a weighted sled may help cancer patients build muscle and lose fat
Disease control OngoingThis pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immunotherapy combo tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New surgical flap aims to restore swallowing and speech in obese tongue cancer patients
Disease control OngoingThis pilot study tests a new surgical technique called the anterolateral thigh myofascial fat composite flap (ALT-MF) for repairing tongue defects after cancer surgery in obese patients (BMI 30 or higher). Traditional flaps can be too bulky in obese patients, leading to problems …
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…
Phase: PHASE1, PHASE2 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
Disease control OngoingThis study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …
Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control TerminatedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could an immunotherapy combo replace harsh chemo for head and neck cancer?
Disease control OngoingThis phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Vitamin a derivative patch could reverse oral precancer
Disease control OngoingThis trial tests a sticky patch that releases fenretinide, a vitamin A derivative, directly onto precancerous spots inside the mouth. The goal is to see if the patch can shrink these lesions, reduce their severity under the microscope, and lower genetic changes linked to oral can…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy-Chemo cocktail shows promise in head and neck cancer trial
Disease control OngoingThis phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental combo targets Chemo-Resistant cancers
Disease control OngoingThis study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …
Phase: PHASE1, PHASE2 • Sponsor: Precision Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune boosting duo takes on rare throat cancer
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink tumors in people with advanced nasopharyngeal carcinoma (NPC) linked to the Epstein-Barr virus. About 113 patients with recurrent or metastatic NPC that can't be cured will r…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase: PHASE1, PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with resistant tumors: drug combo enters safety trial
Disease control OngoingThis early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can radiation wake up the immune system against resistant head and neck cancer?
Disease control OngoingThis phase 2 trial tests whether adding focused radiation to the immunotherapy drug pembrolizumab (Keytruda) can help people with head and neck cancer whose disease has worsened despite prior PD-1 therapy. The study enrolls 18 adults with metastatic or incurable head and neck can…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
DNA vaccine combo takes on HPV head and neck cancer
Disease control OngoingThis phase 2 trial tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in 21 adults with HPV-related head and neck cancer that has returned or spread. The goal is to see if the combo can shrink tumors and improve surviv…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cell therapy aims to fight advanced cancers
Disease control TerminatedThis study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to fight returning head and neck cancer
Disease control OngoingThis study tests a combination of an immunotherapy drug (pembrolizumab) and a type of internal radiation (cesium-131 brachytherapy) given during surgery for head and neck cancer that has come back. The goal is to see if this approach is safe and helps prevent the cancer from retu…
Phase: PHASE1, PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo strategy aims to catch and remove leftover cancer after radiation
Disease control OngoingThis early-phase trial studies whether a combination of regular check-ups, scans, blood tests, and ultrasound can safely find and guide removal of remaining cancer in neck lymph nodes after standard radiation for advanced nasopharyngeal cancer. About 50 adults aged 18-70 with N3 …
Phase: PHASE1 • Sponsor: Guiquan Zhu • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail shows promise in battling advanced head and neck cancer
Disease control OngoingThis study tests whether adding two drugs, niraparib and dostarlimab, to standard radiation therapy can better control advanced head and neck cancer. About 34 adults with stage III or IV cancer will receive the drugs before, during, and after radiation. The goal is to see if this…
Phase: PHASE1, PHASE2 • Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cancer drug injected into tumors shows promise in early trial
Disease control TerminatedThis early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MRI-Guided radiation boost shows promise in head and neck cancer trial
Disease control OngoingThis study tests whether giving an extra dose of radiation to oxygen-poor (hypoxic) areas of head and neck tumors can improve treatment response. About 91 adults with advanced squamous cell cancer of the throat or voice box will receive standard chemo-radiation with or without th…
Phase: PHASE2 • Sponsor: Regina Elena Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo targets Hard-to-Treat nasopharyngeal cancer
Disease control OngoingThis phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has …
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving a combination of three drugs (finotonlimab, cetuximab, and docetaxel) before surgery can shrink tumors in people whose head and neck cancer has come back after prior immunotherapy and chemotherapy. The goal is to see if this approach leads to fewer…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy cocktail shows promise against tough throat cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locoregionally advanced nasopharyngeal carcinoma. About 450 participants will receive either tislelizumab plus chemo or a placebo plus ch…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could less radiation be just as effective for some head and neck cancers?
Disease control OngoingThis study tests whether giving radiation only to the involved lymph nodes (instead of the whole neck area) can control early-stage nasopharyngeal cancer just as well, with fewer side effects. About 414 adults with limited lymph node involvement will be randomly assigned to eithe…
Phase: PHASE3 • Sponsor: Yi Junlin • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Experimental cocktail aims to tackle Hard-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing a new combination of an experimental drug (INCB081776), an immunotherapy (pembrolizumab), and radiation therapy in 10 people with advanced head and neck cancer that has spread or come back. The main goal is to check safety and side effects, while…
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced nasopharyngeal cancer: targeted radiation therapy under study
Disease control TerminatedThis study tests a drug called 177Lu-DOTATATE, which delivers radiation directly to cancer cells, in people with metastatic nasopharyngeal cancer that has not responded to at least two prior treatments. Only patients whose tumors show up on a special scan are eligible. The main g…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise against tough cancers
Disease control OngoingThis early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…
Phase: PHASE1 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for hard-to-treat head and neck cancer: triple therapy trial underway
Disease control OngoingThis study tests a new three-drug combination for people with advanced head and neck cancer that came back or spread after platinum chemotherapy. The drugs aim to boost the immune system and attack cancer cells directly. About 64 adults will take part to see if the treatment is s…
Phase: PHASE2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase: PHASE1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer
Disease control OngoingThis phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer th…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to tame recurrent head and neck cancer
Disease control OngoingThis phase II trial tests a combination of the immunotherapy drug pembrolizumab and a short course of radiation called QUAD SHOT in 30 adults with recurrent head and neck cancer that cannot be cured. The goal is to see if the combination is safe and can shrink tumors or improve q…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Less neck radiation may be just as effective for nasopharyngeal cancer
Disease control OngoingThis study tests whether giving radiation to a smaller area of the neck is as good as the standard larger area for treating nasopharyngeal cancer that hasn't spread. About 474 adults with newly diagnosed cancer will be randomly assigned to one of two radiation plans. The goal is …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Cancer trial aimed at clearing HPV after treatment pulled before starting
Disease control TerminatedThis study was designed for people with HPV-positive oropharyngeal cancer who still had signs of the virus in their blood after completing standard treatment. Researchers planned to give an immunotherapy drug called BALSTILIMAB to see if it could clear the virus and improve long-…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for throat cancer patients: smarter treatments on the horizon
Disease control OngoingThis study tests whether different drug combinations can improve survival and reduce side effects for people with intermediate or high-risk oropharyngeal (throat) cancer. About 785 participants will receive one of several experimental treatments alongside standard chemoradiothera…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial
Disease control OngoingThis phase 2 trial tests the safety and effectiveness of SKB264, a new drug, in 321 adults with advanced solid tumors, specifically non-small cell lung cancer and nasopharyngeal carcinoma. Participants receive SKB264 alone until the drug stops working or side effects become too s…
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Triple threat: new combo targets nasopharyngeal cancer spread
Disease control OngoingThis phase II trial is testing whether combining targeted radiation (SBRT) with an immunotherapy drug (camrelizumab) and standard chemotherapy can help control nasopharyngeal cancer that has spread to a few other parts of the body. The study involves 41 participants who have not …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ZW191 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for hard-to-treat throat cancer
Disease control OngoingThis phase 3 trial tests whether adding the experimental drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18–75 are participating. T…
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy plus chemotherapy shows promise against tough nasopharyngeal cancer
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine can better prevent nasopharyngeal cancer from returning after initial treatment. About 150 patients whose cancer did not fully respond to induction chemotherapy will re…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immune booster added to standard cancer care shows promise in early trial
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard treatment—surgery, radiation, and sometimes chemotherapy—can help people with head and neck cancer live longer without the cancer returning. About 96 participants will receive…
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?
Disease control OngoingThis study tests a shorter, more intense course of radiation therapy (hypofractionated IMRT) given after surgery for head and neck cancer. The goal is to see if it is safe and if it can help patients maintain better swallowing function compared to the standard longer radiation sc…
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug LP-184 tested on tough cancers: hope for Late-Stage patients
Disease control OngoingThis study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…
Phase: PHASE1, PHASE2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cell therapy for advanced gynecological cancers halted before start
Disease control TerminatedThis study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Tiny paclitaxel particles aim to hit tumors harder
Disease control OngoingThis early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug for immunotherapy side effects never tested: trial withdrawn
Disease control TerminatedThis phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…
Phase: PHASE2 • Sponsor: Douglas Johnson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control ENROLLING_BY_INVITATIONThis phase 2 trial is testing whether combining two drugs, pertuzumab and lenvatinib, can shrink tumors before surgery in people with advanced head and neck cancer. About 30 participants will receive 2-4 cycles of the drug combination, then undergo surgery. The main goal is to se…
Phase: PHASE2 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody drug shows promise in fighting advanced cancers
Disease control OngoingThis Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo takes on advanced cancers in early trial
Disease control OngoingThis study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made vaccine takes on tough cancers in early trial
Disease control TerminatedThis early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New three-step combo targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not caused by HPV. First, patients take a drug called palbociclib before standard chemoradiation, then receive chemoradiation, and finally take palbociclib again after treatment. The goal …
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can your own muscle cells fix swallowing? early trial begins
Disease control OngoingThis early-stage trial tests whether injecting a person's own muscle cells into the tongue can safely improve swallowing problems caused by cancer treatment. The study involves 18 adults who had surgery, chemo, or radiation for oropharyngeal cancer at least two years ago. Researc…
Phase: PHASE1 • Sponsor: Peter Belafsky, MD • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New cancer drug ALK-N001 enters early human testing
Disease control TerminatedThis early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…
Phase: PHASE1 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control OngoingThis early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…
Phase: PHASE1 • Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Drug combo targets rare cancers in early trial
Disease control OngoingThis early-phase trial tests the combination of two drugs, vorinostat and azacitidine, in people with nasopharyngeal cancer or nasal NK-T cell lymphoma that has come back or spread. The main goal is to find the safest dose and see how the body responds. Only 18 participants are e…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control OngoingThis study tests whether a much lower dose of radiation (30 Gy) combined with standard chemotherapy works as well as the usual high dose (70 Gy) for people with HPV-positive throat cancer. The goal is to reduce long-term side effects while still controlling the cancer. About 316 …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control OngoingThis study compares a lower dose of radiation to the standard dose for people with HPV-positive throat cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects. The trial involves 23 participants with advanced but non-sprea…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control OngoingThis phase 2 trial tests giving the immunotherapy drug pembrolizumab (Keytruda) along with a short course of targeted radiation before surgery for people with advanced head and neck cancer. The goal is to see if this combination can shrink tumors more effectively and help preserv…
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can less radiation be enough? new trial aims to cut side effects for HPV-linked throat cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemoradiotherapy, given after initial chemotherapy, can effectively treat locally advanced HPV-positive oropharynx cancer while reducing long-term side effects. The study involves 43 participants and tracks how long the canc…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding ramucirumab to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1 positive head and neck cancer that has come back or spread. About 37 participants will receive either the combination or the single drug. Th…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can less radiation after throat surgery be just as effective?
Disease control OngoingThis study looks at people with HPV-positive throat cancer that has spread but can still be removed with surgery. After surgery, some patients get the usual high-dose radiation plus chemo, while others get a lower dose. The goal is to see if the lower dose works just as well and …
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could less radiation be just as good for HPV throat cancer?
Disease control OngoingThis study looks at whether giving a lower dose of radiation after robotic surgery can help people with HPV-positive throat cancer have fewer side effects, like trouble swallowing, while still controlling the cancer. About 33 adults with this type of cancer will receive the reduc…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New immunotherapy combo tested for incurable cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy may replace chemo for some throat cancers
Disease control OngoingThis phase 2 trial compares standard treatment (radiation plus chemotherapy drug cisplatin) against two experimental arms using the immunotherapy drug durvalumab with radiation, followed by either durvalumab alone or durvalumab plus another immunotherapy, tremelimumab. The study …
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for advanced cancer? early trial of 3D185 begins
Disease control OngoingThis early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…
Phase: PHASE1 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Donor immune cells show promise against Virus-Linked cancers
Disease control OngoingThis study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control OngoingThis phase 2 trial tests two different doses of a nano-encapsulated chemotherapy drug called FID-007, combined with cetuximab, in 46 people with advanced head and neck cancer that has returned or spread. The goal is to see how well the combination shrinks tumors and to check for …
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young sarcoma patients: experimental drug combo targets tough tumors
Disease control TerminatedThis study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug HRS-6209 tested in advanced cancer patients
Disease control OngoingThis early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Two-Antibody combo takes on advanced cancers
Disease control OngoingThis study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a few big doses of radiation before surgery beat head and neck cancer?
Disease control OngoingThis early-phase study is testing whether giving a shorter, more intense course of radiation before surgery is safe for people with head and neck cancer. The trial involves 12 adults with HPV-negative, surgically removable tumors. The main goal is to see if this condensed radiati…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug IBI363 aims to supercharge immune system against tough cancers
Disease control OngoingThis early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New targeted therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Blue dye could boost radiation for tough head and neck cancers
Disease control OngoingThis early-phase study tests whether injecting methylene blue (a dye) directly into tumors can make radiation therapy work better for people with head and neck cancer that has come back and is resistant to radiation. Ten participants will receive weekly tumor injections plus dail…
Phase: EARLY_PHASE1 • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Proton beam vs. X-Ray: which radiation is safer for throat cancer?
Disease control OngoingThis phase 3 trial compares two types of radiation therapy for advanced throat cancer: standard photon radiation (IMRT) and newer proton beam therapy (IMPT). The goal is to see if proton therapy causes fewer severe side effects while still controlling the cancer. About 440 patien…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a Chemo-Immunotherapy cocktail spare head and neck cancer patients from radiation?
Disease control OngoingThis phase 2 trial tests a combination of two chemotherapy drugs (carboplatin and nab-paclitaxel) plus an immunotherapy drug (durvalumab) given before surgery for people with locally advanced head and neck cancer. The goal is to shrink or eliminate the tumor so that radiation—whi…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill shows promise against lung cancer in early trial
Disease control OngoingThis study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immune cells trained to fight advanced throat cancer in new trial
Disease control OngoingThis early-phase study tests whether a personalized immune cell therapy (dendritic cells) is safe and can help control advanced nasopharyngeal cancer. The treatment uses the patient's own immune cells and donor cell secretions to boost the body's cancer fight. The study involves …
Phase: PHASE1, PHASE2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug combo aims to reboot immune attack on head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding bavituximab to pembrolizumab can help people with advanced head and neck cancer whose tumors have stopped responding to standard immunotherapy. The study enrolled 7 participants and measures how many tumors shrink or disappear. The goal is …
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase: PHASE1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
HPV vaccine combo shows promise against head and neck cancer in early trial
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see i…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Zapping the brain to kick the habit: rTMS tested for smoking relapse
Disease control OngoingThis study tests repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, to help current smokers quit and avoid relapse. Researchers are enrolling 206 right-handed smokers who smoke 5-25 cigarettes daily and want to quit within 30 days. Th…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug shows promise for Hard-to-Treat throat cancer
Disease control OngoingThis study tests a drug called MRG003 in adults whose nasopharyngeal cancer has come back or spread and hasn't responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 238 participants will receive the drug, and researchers will…
Phase: PHASE2 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hitchhiking drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase: PHASE1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Smart scan could spare half the neck from radiation in head and neck cancer
Disease control OngoingThis study tests whether a special scan (SPECT/CT) can map where a head and neck tumor drains lymph fluid. If the scan shows no drainage to the opposite side of the neck, doctors can safely avoid radiating that side, reducing side effects. About 90 patients with newly diagnosed h…
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy hopes to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…
Phase: PHASE1, PHASE2 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Throat cancer showdown: radiation vs. surgery in HPV patients
Disease control OngoingThis study compares two standard treatments—radiation therapy and surgery—for people with HPV-related throat cancer. The goal is to see which approach provides better survival and quality of life. About 61 adults with early-stage cancer are taking part to help guide future treatm…
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy combo shows promise in shrinking oral tumors before surgery
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, given before surgery to people with oral cavity squamous cell carcinoma. The goal is to see if these drugs can shrink tumors and are safe to use. About 30 adults with tumors larger than 2 cm or lymph node involve…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo aims to improve head and neck cancer outcomes
Disease control OngoingThis study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to reignite immune attack on drug-resistant tumors
Disease control OngoingThis study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy drug may delay cancer's return after surgery
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab can help people with head and neck cancer that has come back after initial treatment. After surgery to remove the recurrent tumor, participants receive pembrolizumab to see if it extends the time before the cancer retu…
Phase: PHASE2 • Sponsor: Assuntina G. Sacco, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Supercharged immune cells take on nasopharyngeal cancer
Disease control OngoingThis early-stage trial tests whether specially trained immune cells (T cells) that are resistant to a cancer's defense protein (TGF-beta) can safely fight EBV-positive nasopharyngeal carcinoma. Fourteen patients with relapsed or hard-to-treat cancer will receive these gene-modifi…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat throat cancer
Disease control OngoingThis phase II trial is testing a combination of three drugs—anlotinib, penpulimab, and capecitabine—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study includes 59 adults aged 18 to 65 who have not had prior systemic therapy for their re…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy plus precision radiation shows promise for Tough-to-Treat head and neck cancers
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to high-precision radiation (SBRT) can help people with head and neck cancer that has come back or is a new tumor in the same area. About 86 participants will receive either the combination o…
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New cell therapy aims to boost cancer fight
Disease control OngoingThis early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests an oral drug called APG-157 given before standard treatment (surgery or radiation) for people with newly diagnosed head and neck cancer. The goal is to see if the drug can shrink tumors and improve outcomes. About 24 adults with early to advanced stage cancer wil…
Phase: PHASE2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New personalized vaccine aims to keep head and neck cancer from returning
Disease control OngoingThis study tests a new personalized immunotherapy called TG4050 for people with advanced head and neck cancer. The treatment is designed to train the immune system to recognize and attack each patient's unique tumor mutations. The goal is to see if it is safe and can help prevent…
Phase: PHASE1, PHASE2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New antibody combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase: PHASE1, PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase: PHASE1, PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a new PET tracer outsmart head and neck cancer metastases?
Diagnosis TerminatedThis Phase II trial investigates whether an experimental imaging agent called 89Zr-panitumumab can better identify metastatic lesions in people with head and neck squamous cell carcinoma. Participants receive the agent intravenously and then undergo PET/CT imaging, which is compa…
Phase: PHASE2 • Sponsor: Andrei Iagaru • Aim: Diagnosis
Last updated Aug 18, 2026 03:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis ENROLLING_BY_INVITATIONThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis TerminatedThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis TerminatedThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Glow-in-the-Dark dye could help detect oral cancer
Diagnosis OngoingThis study tests a fluorescent dye called PARPi-FL that may make oral cancer cells glow during an endoscopic exam. About 23 people with oral squamous cell carcinoma will gargle the dye before surgery, and doctors will check for safety and how well the dye highlights tumors. It is…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
Can a new tracer light up tumors better than standard PET scans?
Diagnosis ENROLLING_BY_INVITATIONThis trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis TerminatedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Simple blood test could spot returning throat cancer sooner
Diagnosis OngoingThis study is testing a blood test that looks for HPV DNA in the blood of people treated for HPV-positive oropharyngeal cancer. The goal is to see if the test can find cancer recurrence earlier than standard follow-up methods. About 150 participants are being followed after treat…
Sponsor: Dana-Farber Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New CT scanner could sharpen view of throat cancer
Diagnosis ENROLLING_BY_INVITATIONThis study tests a new type of CT scan, called Photon-Counting CT, to see if it can more accurately show how far laryngeal cancer has spread. Sixty adults with laryngeal cancer will get this scan while making a sound, which may help separate normal tissues from tumor. The goal is…
Sponsor: Humanitas University • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Glowing dots could help surgeons spot hidden cancer during surgery
Diagnosis OngoingThis study tests a new dye, called cRGDY-PEG-Cy5.5-C dots, to help surgeons see cancer in lymph nodes during head and neck melanoma surgery. About 67 people will receive the dye injection around their tumor before or during surgery. The dye is not a treatment, but may improve how…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Can a simple ultrasound predict immunotherapy success?
Diagnosis TerminatedThis study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…
Phase: NA • Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Surgical sleuthing: new method hunts for hidden cancer origins
Diagnosis OngoingThis study tests a surgical technique called tongue base mucosectomy, combined with detailed tissue analysis, to find the original site of head and neck cancers that have spread to lymph nodes but have no known primary source. About 100 patients will undergo this procedure, and r…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New PET scan agent could predict cancer therapy success, but trial never started
Diagnosis TerminatedThis pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Glowing light could spot oral cancer before it starts
Prevention ENROLLING_BY_INVITATIONThis study investigates whether a painless fluorescent light exam can help find early warning signs of oral cancer in adults. Participants complete a health questionnaire and receive a standard oral exam plus a fluorescence scan. The goal is to see if this simple, non-invasive to…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Could a common diabetes drug stop oral cancer before it starts?
Prevention OngoingThis phase 2 trial tests whether metformin, a widely used diabetes drug, can prevent oral cancer in 26 people with precancerous mouth lesions (leukoplakia or erythroplakia). Participants take metformin by mouth, and researchers check if the lesions shrink or disappear. The goal i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
Can a vaccine stop oral HPV in men with HIV?
Prevention OngoingThis study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…
Phase: PHASE3 • Sponsor: Weill Medical College of Cornell University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Probiotics may shield cancer patients from Immunotherapy's gut woes
Prevention TerminatedThis study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …
Phase: NA • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Can a smartphone app help young cancer survivors get moving and improve their quality of life?
Symptom relief OngoingThis study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Miracle fruit tested as taste saver for head and neck cancer patients
Symptom relief OngoingThis phase 3 trial tests whether a 'miracle fruit' cube (miraculin) can improve taste loss in head and neck cancer patients undergoing radiation therapy. Taste problems are common and hard to treat during radiation. The study will compare the fruit cube to a placebo in 40 patient…
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Cancer breathlessness study: can opioids help you walk easier?
Symptom relief OngoingThis study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a sugar pill you know is fake fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief ENROLLING_BY_INVITATIONThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Veterans with cancer get help discussing End-of-Life wishes in group sessions
Symptom relief OngoingThis study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…
Phase: NA • Sponsor: VA Palo Alto Health Care System • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can two existing drugs help cancer patients ditch steroids?
Symptom relief OngoingThis study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…
Phase: PHASE2 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Heart help for cancer survivors: exercise and diet study launches
Symptom relief OngoingThis study looks at whether exercise training and dietary counseling can help cancer survivors who have heart failure. About 85 participants will either receive usual care or join a program with exercise three times a week and low-salt diet guidance. The goal is to see if this li…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a calming drug combo bring clarity to cancer patients?
Symptom relief OngoingThis study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Can writing about cancer help young survivors heal?
Symptom relief OngoingThis study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief OngoingThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Sniffing away sickness: essential oils tested for chemo nausea
Symptom relief TerminatedThis trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Mouth rinse could ease painful radiation side effects for head and neck cancer patients
Symptom relief OngoingThis trial tests Gelclair, a mouth rinse that forms a protective coating over the mouth's lining, to see if it eases the painful mouth sores (oral mucositis) caused by radiation therapy for head and neck cancer. The study enrolls adults with squamous cell carcinoma who will recei…
Phase: PHASE4 • Sponsor: McMaster University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase: PHASE2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Could a single doctor visit reduce cancer distress?
Symptom relief ENROLLING_BY_INVITATIONThis study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…
Phase: NA • Sponsor: Ellis Medicine • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New drug aims to spare cancer patients from debilitating mouth sores
Symptom relief OngoingThis phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief TerminatedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could an herbal patch ease pain after cancer?
Symptom relief OngoingThis study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New support program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Phase: NA • Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to tackle loneliness in cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Can a simple fluoride treatment save teeth after cancer radiation?
Symptom relief OngoingThis pilot study looks at whether giving fluoride varnish during regular cancer checkups can help protect the teeth of head and neck cancer patients who have had radiation and lack easy access to a dentist. About 43 uninsured or underinsured adults will receive 4-5 fluoride treat…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could a phone call replace the clinic visit for throat cancer Follow-Up?
Symptom relief OngoingThis study compares standard in-person follow-up care with telemedicine (phone or video visits) for people who have finished treatment for HPV-related throat cancer and show no signs of cancer on scans. The goal is to see which approach better maintains quality of life, detects a…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Phase: NA • Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New study tests safer pain relief for oral cancer patients
Symptom relief ENROLLING_BY_INVITATIONThis study compares two pain management strategies for adults with oral cancer who have moderate to severe pain. One group receives the opioid tramadol, while the other gets a combination of pregabalin and naproxen sodium. Over 7 days, researchers measure pain reduction, side eff…
Phase: NA • Sponsor: Mayo Hospital Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a cheap gout pill soothe radiation burns?
Symptom relief OngoingThis early-stage study tests whether a low dose of colchicine, a medicine usually used for gout, can safely reduce skin redness and pain caused by radiation therapy in people with head and neck cancer. About 30 participants take one pill daily during their radiation treatment. Th…
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Talking hope: new therapy aims to lift spirits of cancer patients during radiation
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can a virtual sleep program help cancer survivors beat insomnia?
Symptom relief OngoingThis study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Fitbit and app aim to boost activity in cancer survivors
Symptom relief OngoingThis study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…
Phase: NA • Sponsor: The University of Tennessee, Knoxville • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New toolkit aims to boost recovery for older cancer surgery patients
Symptom relief OngoingThis study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can squeezing hands and feet stop chemo nerve pain?
Symptom relief OngoingThis study tests whether wearing pressurized gloves and foot caps during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by the drug paclitaxel. It involves 182 people with nasopharyngeal cancer who have not yet started treatment. Each patient serves as their…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Which tube feeding method works best for head and neck cancer patients?
Symptom relief TerminatedThis study aimed to compare three tube feeding methods—bolus, gravity, and pump—in 60 head and neck cancer patients undergoing chemoradiation. The goal was to see which method leads to the least weight loss and best tolerance. However, the trial was withdrawn before any patients …
Phase: NA • Sponsor: Baylor Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can an iPad program help older cancer patients stay strong?
Symptom relief OngoingThis study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Could One-Sided radiation be safer for throat cancer patients?
Symptom relief OngoingThis study looks at whether people with throat cancer on one side of the neck can safely receive radiation to only that side, instead of both sides. The goal is to reduce side effects from unnecessary radiation. About 8 participants with early-stage HPV-related tonsil or tongue b…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fitbit for cancer care: new study tests remote exercise monitoring
Symptom relief OngoingThis study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Can online yoga help cancer survivors sleep better?
Symptom relief OngoingThis study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can yoga and relaxation help young cancer survivors? new study tests a Stress-Busting program
Symptom relief OngoingThis study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Can a smartphone app help oral cancer patients recover faster?
Symptom relief OngoingThis study tests whether a remote rehabilitation app can improve shoulder and neck recovery in oral cancer patients who had neck dissection surgery. 80 patients are randomly assigned to either standard home exercise materials or the app, which provides daily reminders and lets pa…
Phase: NA • Sponsor: Pai Pang • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Phase: NA • Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a cornstarch powder get you home faster after surgery?
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a starch-based powder called 4DryField PH, placed in the wound during head and neck surgery, can reduce the amount of fluid that drains out afterward. The goal is to shorten how long drainage tubes stay in and possibly reduce hospital stays. Sixty adults …
Phase: NA • Sponsor: Taichung Veterans General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a smartphone app help rural cancer patients beat the odds?
Symptom relief OngoingThis study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Knee pain study for cancer patients pulled before starting
Symptom relief TerminatedThis study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pain relief study for cancer patients withdrawn before starting
Symptom relief TerminatedThis trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New online program aims to restore sexual health in young cancer survivors
Symptom relief OngoingThis study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Yoga for two: could partner sessions cut hospital visits for cancer patients?
Symptom relief OngoingThis study looks at whether a partner-based (dyadic) yoga program can improve quality of life and reduce hospital visits for head and neck cancer patients undergoing chemoradiation, as well as their family caregivers. About 415 patient-caregiver pairs are taking part. The yoga se…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Exercise boosts quality of life in cancer patients, study finds
Symptom relief OngoingThis study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…
Sponsor: University of Castilla-La Mancha • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Antidepressant drug could fight cancer fatigue
Symptom relief OngoingThis phase 3 trial tests whether bupropion, a drug used for depression and smoking cessation, can reduce fatigue in 422 cancer survivors. Participants have stable disease or no evidence of cancer and report moderate to severe fatigue. They receive either bupropion or a placebo, a…
Phase: PHASE3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Cancer drug interaction study: will antibiotics change how cediranib works?
Knowledge-focused OngoingThis Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Can cancer patients get better care at home? MD anderson investigates
Knowledge-focused TerminatedThis study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New tool lets young cancer patients speak up about symptoms
Knowledge-focused OngoingThis study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused TerminatedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to perfect chemo dosing for cancer patients
Knowledge-focused OngoingThis study looks at whether a dye called iohexol can help doctors better calculate the dose of the chemotherapy drug carboplatin for cancer patients. The goal is to make sure patients get the right amount of drug to fight their cancer while reducing side effects. About 318 men wi…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Cancer tissue bank study aims to unlock new treatment clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a smartphone app get young cancer survivors moving? new study aims to find out.
Knowledge-focused OngoingThis study looks at whether a mobile health program combined with social media can help teens and young adults who survived childhood cancer become more physically active. About 387 participants will either use the program plus a fitness tracker or just the tracker alone. The goa…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Phase: NA • Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New PET scans reveal how Immune-Boosting drugs target tumors
Knowledge-focused OngoingThis study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused TerminatedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
Knowledge-focused OngoingThis large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Gene test could personalize cancer drug dosing
Knowledge-focused OngoingThis study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
Knowledge-focused OngoingThis trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
AI model aims to end guesswork in head and neck cancer care
Knowledge-focused ENROLLING_BY_INVITATIONThis study uses an AI model to analyze patient data and recommend the best follow-up treatment after surgery for advanced head and neck cancer. Researchers will track 571 patients over two years to see if the AI's suggestions improve survival and reduce recurrence. The goal is to…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New DNA test aims to predict bloodstream infections in kids with cancer
Knowledge-focused OngoingThis study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Can a simple sheet of paper improve cancer care conversations?
Knowledge-focused OngoingThis study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New study tracks throat cancer Patients' symptoms after radiation
Knowledge-focused OngoingThis study looks at symptoms reported by patients with oropharyngeal cancer after they finish radiation or chemoradiation. Researchers will review medical records and have patients complete questionnaires about their symptoms. The goal is to learn more about what patients experie…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Pharmacist-Led lessons may cut infection risk in chemo patients
Knowledge-focused OngoingThis trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …
Phase: NA • Sponsor: Jordan University of Science and Technology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New platform aims to personalize cancer treatment for GI patients
Knowledge-focused OngoingThis study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…
Sponsor: Brigette Ma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may predict ICU death risk for cancer patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks cancer patients at home to improve care
Knowledge-focused OngoingThis study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to catch hidden head and neck cancer early
Knowledge-focused OngoingThis study is testing whether a blood test can find tiny bits of tumor DNA (ctDNA) or HPV DNA in patients with high-risk head and neck cancer after standard treatment. The goal is to see if this test can detect cancer that remains or comes back earlier than usual scans. The study…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer patients' family talks about genetic surprises studied
Knowledge-focused OngoingThis study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Microdose cancer drug test could reveal best treatments without side effects
Knowledge-focused OngoingThis early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…
Phase: EARLY_PHASE1 • Sponsor: Presage Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused TerminatedThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Phase: EARLY_PHASE1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
3D tumor maps could sharpen radiation targeting in head and neck cancer
Knowledge-focused OngoingThis study tests whether creating a virtual 3D map of a patient's removed tumor helps doctors plan radiation therapy more precisely. Researchers will compare standard radiation plans with plans that include the 3D map to see if it changes the treatment area or reduces radiation t…
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can a Tumor's 'Neighborhood' predict drug success?
Knowledge-focused OngoingThis study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase: PHASE2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New app helps cancer patients get housing and food support
Knowledge-focused OngoingThis study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Massive 75,000-Patient registry aims to unlock best uses of proton therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can a statin tame a cancer protein? early trial seeks answers
Knowledge-focused OngoingThis early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…
Phase: PHASE1 • Sponsor: Joaquina Baranda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI reads scans to forecast cancer treatment success
Knowledge-focused OngoingThis study tests whether artificial intelligence (AI) can analyze medical scans (CT, MRI, PET) to predict how well head and neck cancer patients will respond to radiation therapy and whether they will have side effects. The goal is to personalize treatment for better outcomes. Ab…
Phase: NA • Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Can new outreach methods boost minority enrollment in cancer trials?
Knowledge-focused OngoingThis study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can injecting immunotherapy directly into tumors boost the body's fight against head and neck cancer?
Knowledge-focused OngoingThis study is for 18 adults with head and neck cancer who are already scheduled for surgery. Researchers want to see if it is safe and possible to inject the drug ipilimumab directly into the tumor a few weeks before the operation. The main goal is to check if this approach delay…
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused ENROLLING_BY_INVITATIONThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Simple senior health quiz may predict chemo dangers
Knowledge-focused OngoingThis study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can tablets replace paper for senior cancer patients?
Knowledge-focused OngoingThis study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Cancer gene hunt: 21,000 Patients' DNA scoured for clues
Knowledge-focused OngoingThis study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to better detect depression in older adults with cancer
Knowledge-focused OngoingThis study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Does more frequent Check-Ups after head and neck cancer save lives?
Knowledge-focused OngoingThis study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. The goal is to …
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New tool aims to predict chemo risks for seniors
Knowledge-focused OngoingThis study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to improve cancer pain management
Knowledge-focused OngoingThis study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New approach aims to boost cancer trial awareness and participation
Knowledge-focused OngoingThis study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Real-Time proton beam tracking could sharpen cancer therapy
Knowledge-focused OngoingThis study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …
Sponsor: Shuanghu Yuan • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Radiation's hidden toll: new study tracks late effects in NPC survivors
Knowledge-focused OngoingThis study follows 108 nasopharyngeal cancer survivors who had radiation and chemotherapy at least four years ago. Researchers are measuring long-term side effects like hormone problems, hearing loss, and memory issues using blood tests, cognitive exams, and quality-of-life surve…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can special MRIs predict cancer treatment outcomes?
Knowledge-focused OngoingThis study uses three advanced MRI techniques to see if they can predict how well head and neck cancer patients will respond to surgery or chemo-radiation. About 272 adults with head and neck cancer will get these scans before and early during treatment. The goal is to find marke…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Cancer test study pulled before it even started
Knowledge-focused TerminatedThis study planned to check if a new test, called OncoPrism-HNSCC, could predict how well immunotherapy would work in people with head and neck cancer that had spread. Researchers would have looked at tumor samples taken before treatment to see if the test could tell who would be…
Sponsor: Cofactor Genomics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Saliva test for head and neck cancer? new study explores microRNA clues
Knowledge-focused OngoingThis study collects saliva, blood, and tissue samples from 225 people with and without head and neck cancer. Researchers look for tiny genetic markers called microRNAs that might help diagnose the disease or predict how it will progress. The goal is to develop a simple, non-invas…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Why do cancer patients fear painkillers? new study investigates
Knowledge-focused OngoingThis study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
New study aims to personalize throat cancer treatment using genetic tests and MRI
Knowledge-focused OngoingThis study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast t…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Radiation's hidden toll: study tracks Long-Term dental damage in cancer patients
Knowledge-focused OngoingThis study follows 100 head and neck cancer patients receiving standard radiotherapy to see how their teeth, gums, and saliva change over time. Researchers measure gum health, tooth condition, and quality of life before and after treatment. The goal is to better understand these …
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Could less radiation be enough for HPV throat cancer? new study investigates
Knowledge-focused OngoingThis study looks at whether a lower dose of radiation can safely treat HPV-positive oropharynx (throat) cancer in people who have never smoked or smoked very little. Researchers will follow 75 patients for up to 5 years to see if the cancer stays away and how their quality of lif…
Sponsor: Sanford Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
App-Based symptom tracker for recurrent cancer patients tested — but study withdrawn
Knowledge-focused TerminatedThis pilot study aimed to see if a mobile health app could help track symptoms and quality of life in people with recurrent head and neck or gynecologic cancers. Participants would have used the app to report their feelings, side effects, and barriers to care. However, the study …
Phase: NA • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Phase: NA • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Light therapy under the microscope: can it soothe mouth sores after transplant?
Knowledge-focused OngoingThis study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New MRI technique may reveal cancer treatment effects earlier
Knowledge-focused OngoingThis study tests whether a special type of MRI, called diffusion MRI, can accurately measure how head and neck tumors change during chemotherapy and radiation. Researchers will scan 16 patients before and during treatment to see if the MRI can predict whether the cancer shrinks o…
Phase: NA • Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Expert panel boosts precision cancer care in new study
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New imaging agent could help spot tumors in future cancer trials
Knowledge-focused OngoingThis early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused TerminatedThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New study seeks sharper MRI images for cancer treatment
Knowledge-focused TerminatedThis study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Timing of shoulder exercises may boost recovery after neck cancer surgery
OngoingThis study looks at whether starting scapular-focused exercises early after neck dissection helps head and neck cancer patients regain shoulder function better than waiting. Participants are adults aged 20–65 with shoulder issues after surgery. They will do weekly 60-minute exerc…
Phase: NA • Sponsor: National Taiwan University Hospital
Last updated Jul 23, 2026 00:00 UTC